US Markets
Home›US Markets›Equities›Why Is Vir Biotechnology Stock Falling Friday?
Why Is Vir Biotechnology Stock Falling Friday?
Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10 per share, raising concerns about shareholder dilution . $150 Million Equity Offering Vir Biotechnology priced 15 million common shares at $10 each, expecting gross proceeds of $150 million before underwriting discounts, commissions, and expenses. The company granted underwriters a 30-day option to purchase up to 2.25 million additional shares. The option allows purchases at the offering price, less underwriting disc
Latest closeNasdaq Comp. 25,074.85 ▼1.1%
← Newer storyHours-Long Microsoft Outage Disrupts Businesses, Governments GloballyOlder story →US PPI Slows Sharply to 0.3%, but Underlying Price Pressures Stay Firm